Sarepta Therapeutics Zooms Higher on Early Data Rally Promising
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Choosing the right rewards program can significantly impact your benefits. Learn which one suits you best.
27,839 articlesSarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Trump backs down on the controversial anti-weaponization fund, clearing the path for immigration enforcement funding ...
Negotiations opened amid heated rhetoric from Washington and Tehran, threatening to slow progress. Analysts warn that...
Morgan Stanley halves Lucid's price target to $5, keeping an Underweight rating as production stoppages and a leaders...
Hollywood, Florida leverages Live Local 4.0 to force a county decision on a Related Group beachfront project, signali...
A historic Knicks championship ends a 53-year wait and offers practical leadership and personal finance lessons on pa...
European defense funding is moving to multi-year commitments, reshaping orders for European and U.S. defense contract...
SpaceX is exploring an IPO designed for everyday investors, outlining a plan to list shares and fund its space infras...
A celebrity’s plea highlights a bigger money issue: how newborn SMA screening decisions touch family budgets. This gu...
Strategic ambiguity around Bitcoin holdings prompted fresh market jitters as Michael Saylor hinted at selling a porti...
Chevron stock climbs as crude prices rise, stoking debate on how high it can go this year. Analysts point to Hess syn...
A roundup of Thursday’s best wall street analyst calls highlights notable upgrades and price targets across Brown-For...